Overview

A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Aripiprazole
Aripiprazole lauroxil